Johnson & Johnson Announced At ESMO Saturday, Phase 3 PROTEUS Substudy Data Showing Perioperative Apalutamide Plus ADT Reduced Risk Of Disease Recurrence Or Death By 62%, Metastasis Or Death By 51% Vs. Surgery Alone In High-Risk Prostate Cancer
Johnson & Johnson Announced At ESMO Saturday, Phase 3 PROTEUS Substudy Data Showing Perioperative Apalutamide Plus ADT Reduced Risk Of Disease Recurrence Or Death By 62%, Metastasis Or Death By 51% Vs. Surgery Alone In High-Risk Prostate Cancer
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed